Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2560110 | 0.80 | SIGMAR1 (0.45) | KDM4EALDH1A1SIGMAR1MEN1KMT2A | |
| SCHEMBL3398936 | 0.80 | SIGMAR1 (0.48) | KDM4EALDH1A1SIGMAR1TSHRKCNH2 | |
| SCHEMBL430014 | 0.80 | POLB (0.53) | SIGMAR1MEN1KMT2AKCNH2HTR2B | |
| SCHEMBL1516726 | 0.78 | TSHR (0.52) | KDM4EALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL2555039 | 0.77 | KDM4E (0.60) | KDM4EALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL3118354 | 0.77 | GAA (0.48) | KDM4EALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL460929 | 0.76 | SIGMAR1 (0.46) | KDM4EALDH1A1SIGMAR1TSHRKCNH2 | |
| SCHEMBL445617 | 0.76 | HRH2 (0.51) | KDM4EALDH1A1SIGMAR1TSHRCYP1A2 | |
| SCHEMBL942887 | 0.76 | SIGMAR1 (0.44) | ALDH1A1SIGMAR1MEN1KMT2AKCNH2 | |
| SCHEMBL460928 | 0.76 | KDM4E (0.45) | KDM4EALDH1A1SIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| EP-2268612-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | MMP11, MMP10, MMP9 | KDM4E 1013/4885ALDH1A1 715/4885SIGMAR1 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.